TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics (NASDAQ: TCRX) announced preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101 for blood cancers. The trial enrolled 27 patients, with 16 in the treatment arm and 11 in the control arm. Key findings showed no relapses in the treatment arm versus three relapses in the control arm, with a median time to relapse of 159 days in the control group. All five TSC-treated patients reaching one-year follow-up remained relapse-free and MRD negative. No dose-limiting toxicities were reported, and safety profiles were similar between treatment and control arms.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houston, TX and virtually.

The presentations include:

• Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
• Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
• Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human Tissues

All presentations will take place in the Exhibit Halls AB at the George R. Brown Convention Center. The presentation materials will be available on TScan's website after the event concludes.

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment, has announced its participation in two upcoming investor conferences:

1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5, 2024, at 8:30 a.m. ET at the New York Marriott Marquis.

2. H.C. Wainwright 26th Annual Global Investment Conference: Presentation on September 10, 2024, at 9:00 a.m. ET at the Lotte New York Palace Hotel.

Webcasts of both events will be available on TScan's website under the "Events and Presentations" section, with archived replays accessible for 90 days post-event.

TScan Therapeutics (Nasdaq: TCRX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. FDA granted RMAT designation to TSC-100 and TSC-101 for treating AML, ALL, and MDS patients undergoing allogeneic HCT.

2. Engaged a global CDMO for pivotal trials and commercialization manufacturing support.

3. On track to report initial solid tumor program data and one-year ALLOHA Phase 1 heme trial data by end of 2024.

4. Cash position of $297.7 million, funding operations into Q4 2026.

5. Q2 2024 revenue: $0.5 million; R&D expenses: $26.9 million; G&A expenses: $7.8 million; Net loss: $31.7 million.

6. Anticipating expansion cohorts opening in Q3 2024 and initiation of a registration trial in 2025.

TScan Therapeutics, a clinical-stage biopharmaceutical company, announced changes to its Board of Directors. Garry A. Nicholson, an executive with extensive regulatory and commercial expertise, has joined the board. Timothy Barberich has retired as Chair, and Stephen Biggar, M.D., Ph.D., a current board member, will assume the role of Chair. CEO Gavin MacBeath highlighted Nicholson's 35+ years of oncology experience, including his tenure as president of Pfizer Oncology. Nicholson will support TScan’s mission to advance T cell receptor-engineered therapies for cancer. Barberich, who joined the board in 2019 and served as Chair since 2021, was acknowledged for his contributions. Biggar, a board member since 2021, steps into the leadership role. Nicholson's background includes leadership roles at Pfizer, Eli Lilly, and XTuit Pharmaceuticals, as well as board positions at several biotech companies.

TScan Therapeutics (Nasdaq: TCRX) announced its participation in the Jefferies Global Healthcare Conference, scheduled for June 5, 2024, at 11:00 a.m. ET at the Marriott Marquis in New York, NY. The company, which is focused on developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, will present during the conference. A live webcast of the presentation will be available on TScan's website, with a replay accessible for 90 days post-event.

TScan Therapeutics announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead TCR-T therapy candidates, TSC-100 and TSC-101, for treating heme malignancies, including AML, ALL, and MDS. The RMAT designation is based on encouraging data from the ALLOHA trial and aims to expedite the development of transformative therapies. Both candidates target minor histocompatibility antigens HA-1 and HA-2 to eliminate malignant cells in patients undergoing allogeneic HCT with reduced intensity conditioning. Initial trial data show promising results with no relapse in treated patients and no dose-limiting toxicities observed.

TScan Therapeutics, Inc. (Nasdaq: TCRX) reported financial results for Q1 2024, dosing the first patient in its Phase 1 solid tumor program. All Phase 1 heme program patients remain relapse-free. A public offering raised $167.8 million, extending funds into Q4 2026. The company presented at major medical meetings and plans poster presentations at ASCO. TScan aims to advance heme and solid tumor programs with upcoming milestones.

TScan Therapeutics announced the dosing of the first patient in a Phase 1 clinical trial for TCR-T therapy targeting solid tumors, with initial data expected in 2024. The company aims to expand its ImmunoBank to enhance multiplex TCR-T therapy for solid tumors.